Everist Announces Advance In Diagnosis, Prognosis Of Colorectal CancerEverist Genomics, a rapidly growing personalized medicine company, today announced the launch of the world's first comprehensive companion diagnostics and prognostics portfolio to improve early diagnosis, management and treatment of patients with colorectal cancer.
Rubicon Genomics Signs Deal For Technology With AgendiaAnn Arbor-based Rubicon Genomics Inc. said Thursday that it had a new clinical supply agreement with the Amsterdam, Netherlands-based diagnostics firm Agendia.